金吾财讯 | 瑞士罗氏公司于本周二宣布，计划以每股9美元的价格收购位于加州的生物制药企业Poseida Therapeutics，收购完成后，该公司的总股本价值将达到10亿美元。此外，罗氏还提出，Poseida的股东将额外获得每股4美元的不可交易的或有价值权（CVR），使得此次交易的总价值最高可达约15亿美元。预计该交易将在2025年的第一季度内完成。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.